Physician profile
Jamal Azem
NPI 1518061811
$1,480.95
in general payments reported to CMS, 2019-2025
23 companies · $71.98 in 2025
The $71.98 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $580 · 2020: $242 · 2021: $54.45 · 2022: $130 · 2023: $158 · 2024: $245 · 2025: $71.98.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $408 · Education: $66.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $408.19 |
| Education | $66.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $211.49 | 2019-2023 | Korsuva, Veltassa |
| Otsuka America Pharmaceutical, INC. | $207.34 | 2019-2025 | Jynarque |
| Astrazeneca Pharmaceuticals Lp | $192.43 | 2019-2022 | |
| Opko Pharmaceuticals, LLC | $158.20 | 2019-2020 | |
| Travere Therapeutics, INC. | $94.13 | 2023-2024 | |
| Glaxosmithkline, LLC. | $85.49 | 2022-2023 | Jesduvroq, Benlysta |
| Akebia Therapeutics INC | $62.56 | 2019 | |
| Novartis Pharmaceuticals Corporation | $61.55 | 2024-2025 | |
| Xeris Pharmaceuticals, INC. | $53.54 | 2024 | Keveyis |
| Mallinckrodt Hospital Products INC. | $52.50 | 2020-2024 | Terlivaz |
| Amgen INC. | $51.56 | 2019-2024 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $44.03 | 2021-2024 | |
| Fresenius USA Marketing, INC. | $34.62 | 2019-2020 | |
| Shire North American Group INC | $25.98 | 2019 | |
| Calliditas Therapeutics US INC. | $22.50 | 2024 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $21.20 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $17.20 | 2024 | Jardiance |
| Novo Nordisk INC | $17.15 | 2024 | Wegovy |
| Ardelyx, INC. | $15.44 | 2024 | Ibsrela |
| Scpharmaceuticals INC. | $13.57 | 2025 | |
| Baxter Healthcare | $13.42 | 2019 | |
| Mallinckrodt Enterprises LLC | $13.23 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $11.82 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jamal Azem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.